111 related articles for article (PubMed ID: 15779382)
21. [Pathophysiological conditions progressing from impaired glucose tolerance: type 2 diabetes mellitus].
Asakura T; Ito Y
Nihon Rinsho; 2005 Feb; 63 Suppl 2():237-41. PubMed ID: 15779378
[No Abstract] [Full Text] [Related]
22. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
Zeymer U
Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
[TBL] [Abstract][Full Text] [Related]
23. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
Liebl A
Med Klin (Munich); 2003 Oct; 98 Suppl 1():7-11. PubMed ID: 14694835
[TBL] [Abstract][Full Text] [Related]
24. Prevention of type 2 diabetes in the prediabetic population.
Maji D; Roy RU; Das S
J Indian Med Assoc; 2005 Nov; 103(11):609-11. PubMed ID: 16570766
[TBL] [Abstract][Full Text] [Related]
25. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
Kirkman MS; Shankar RR; Shankar S; Shen C; Brizendine E; Baron A; McGill J
Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
[TBL] [Abstract][Full Text] [Related]
26. [Dyslipidemia management in patients with impaired glucose tolerance].
Asano M; Yamada N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():538-42. PubMed ID: 15779437
[No Abstract] [Full Text] [Related]
27. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.
Hung YJ; Lin SH; Pei D; Kuo SW; Hsieh CH; He CT; Hsing Lee C; Fan SC; Sheu WH
Metabolism; 2006 Apr; 55(4):439-44. PubMed ID: 16546473
[TBL] [Abstract][Full Text] [Related]
28. [Dangerous postprandial glucose peaks. Risk for heart and blood vessels].
MMW Fortschr Med; 2002 May; 144(21):58. PubMed ID: 12134432
[No Abstract] [Full Text] [Related]
29. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
30. [Pathophysiological conditions progressing from impaired glucose tolerance: high blood pressure].
Katayama S
Nihon Rinsho; 2005 Feb; 63 Suppl 2():242-5. PubMed ID: 15779379
[No Abstract] [Full Text] [Related]
31. [Management of blood glucose--target of the management and its practice].
Ishibashi S
Nihon Rinsho; 2006 Nov; 64(11):2089-94. PubMed ID: 17087301
[TBL] [Abstract][Full Text] [Related]
32. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.
Chang AM; Smith MJ; Bloem CJ; Galecki AT; Halter JB
Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E906-11. PubMed ID: 15213063
[TBL] [Abstract][Full Text] [Related]
33. Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Preiss D; Giles TD; Thomas LE; Sun JL; Haffner SM; Holman RR; Standl E; Mazzone T; Rutten GE; Tognoni G; Chiang FT; McMurray JJ; Califf RM
Stroke; 2013 Sep; 44(9):2590-3. PubMed ID: 23899915
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K
Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368
[TBL] [Abstract][Full Text] [Related]
35. [From cardiovascular risk to chronic heart failure].
Ertl G
Med Klin (Munich); 2003 Oct; 98 Suppl 1():17. PubMed ID: 14694837
[No Abstract] [Full Text] [Related]
36. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
[TBL] [Abstract][Full Text] [Related]
37. Drugs for type 2 diabetes.
Treat Guidel Med Lett; 2008 Jul; 6(71):47-54. PubMed ID: 18583949
[No Abstract] [Full Text] [Related]
38. Postprandial hyperglycemia: are all sulfonylureas created equal?
Kapoor JR
Am J Cardiol; 2008 Feb; 101(4):554-5. PubMed ID: 18312779
[No Abstract] [Full Text] [Related]
39. Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy.
Zeymer U; Schwarzmaier-D'assie A; Petzinna D; Chiasson JL;
Eur J Cardiovasc Prev Rehabil; 2004 Oct; 11(5):412-5. PubMed ID: 15616415
[TBL] [Abstract][Full Text] [Related]
40. Dysglycemia/prediabetes and cardiovascular risk factors.
Hanna-Moussa A; Gardner MJ; Kurukulasuriya LR; Sowers JR
Rev Cardiovasc Med; 2009; 10(4):202-8. PubMed ID: 20065930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
